S. Larson

Publications1,025
h-index125
Citations54,084
Highly Influential Citations1,313
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • H. Scher
  • 1,137 Publications • 104,175 Citations
  • M. Morris
  • 487 Publications • 21,236 Citations
  • J. Humm
  • 429 Publications • 18,320 Citations
  • J. Carrasquillo
  • 392 Publications • 14,143 Citations
  • Publications
  • Influence
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
View on Elsevier
Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis.
View on PubMed
Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute Trials.
TLDR
This paper presents a meta-modelling study of the response of positron emission tomography (PET) to radiolysis (radiolysis) and its applications to nuclear medicine and Radiology.
View on PubMed
Segmentation of lung lesion volume by adaptive positron emission tomography image thresholding
TLDR
The authors focus on the specification of appropriate volumes of interest (VoI) using PET in association with computed tomography (CT) to quantitate accurately the activity and volume of lesions and organs with positron emissiontomography (PET).
View on Wiley
Genetically Targeted T Cells Eradicate Systemic Acute Lymphoblastic Leukemia Xenografts
TLDR
The finding that modifications in CAR design as well as T-cell dosing allowed for the complete eradication of systemic disease affects the design of clinical trials using this treatment strategy.
View on Publisher
Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma.
TLDR
FDG uptake is lower in indolent than in aggressive lymphoma, and patients with NHL and SUV > 10 have a high likelihood for aggressive disease.
View on PubMed
Circulating Tumor Cell Number and Prognosis in Progressive Castration-Resistant Prostate Cancer
TLDR
Baseline CTC number was strongly associated with survival, without a threshold effect, which increased further when baseline prostate-specific antigen and albumin were included, and was predictive of survival, with no threshold effect.
View on Publisher
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
TLDR
Its potential to facilitate drug development in seven oncologic settings (lung, lymphoma, breast, prostate, sarcoma, colorectal, and ovary) is addressed and its potential as a surrogate of clinical benefit is addressed.
View on Publisher
Patterns of (18)F-FDG uptake in adipose tissue and muscle: a potential source of false-positives for PET.
TLDR
Increased (18)F-FDG uptake is sometimes seen in individual muscles and in adipose tissue in the neck and shoulder region, axillae, mediastinum, and perinephric regions, and it is important to recognize this uptake pattern to avoid false interpretation of this benign normal variant as a malignant finding on (18).
View on PubMed
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
TLDR
Selumetinib produces clinically meaningful increases in iodine uptake and retention in a subgroup of patients with thyroid cancer that is refractory to radioiodine; the effectiveness may be greater in patients with RAS-mutant disease.
View on PubMed
...
...